Herpes simplex virus vaccine
View Patent ↗Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
1. A nucleic acid comprising one or more of the following:
(a) a nucleic acid sequence with at least 74.5% identity to SEQ ID NO: 1,
(b) nucleic acid sequence encoding an amino acid sequence with at least 97% identity to SEQ ID NO: 2, and
(c) a nucleic acid sequence with at least 82.5% identity to SEQ ID NO: 5.
2. A vector comprising the nucleic acid of claim 1 .
3. The vector of claim 2 , wherein the vector is a viral vector or a plasmid.
4. The vector of claim 3 , wherein the vector is a poxvirus.
5. The vector of claim 3 , wherein the vector is a vaccinia virus.
6. The vector of claim 3 , wherein the vector is an adeno-associated vector.
7. The vector of claim 3 , wherein the vector is an adenoviral vector.
8. The vector of claim 3 , wherein the adenoviral vector comprises an adenoviral genome, and wherein a gorilla adenovirus is the source of the adenoviral genome.
9. The vector of claim 8 , wherein the gorilla adenovirus comprises 70% or more identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, and combinations thereof.
10. The vector of claim 7 , wherein the adenoviral vector requires at most complementation of a deficiency in one or more early regions of the adenoviral genome for propagation.
11. The vector of claim 7 , wherein the adenoviral vector comprises a deletion of all or part of the E3 region of the adenoviral genome.
12. A polypeptide encoded by the nucleic acid of claim 1 .
13. A composition comprising a pharmaceutically acceptable carrier and one of (a)-(c):
(a) the nucleic acid of claim 1 ,
(b) one of more vectors comprising the nucleic acid of claim 1 ,
(c) a polypeptide encoded by the nucleic acid of claim 1 .
14. A method of inducing an immune response against Herpes Simplex Virus (HSV) in a mammal, which method comprises administering to the mammal the composition of claim 13 , whereupon an immune response against HSV is induced in the mammal.
15. A method of treating or preventing a Herpes Simplex Virus (HSV) disease in a mammal, which method comprises administering to mammal the mammal the composition of claim 13 , whereupon a HSV disease is treated or prevented in the mammal.
16. A method of inducing a T cell response against Herpes Simplex Virus (HSV) in a mammal, which method comprises administering to the mammal the mammal the composition of claim 13 , whereupon a T cell response against HSV is induced in the mammal.
17. A method of inducing an immune response against Herpes Simplex Virus (HSV) in a mammal, which method comprises administering to the mammal a first administration of a composition and at least one additional administration of the same or different composition, wherein each of the administrations comprises the vector of claim 2 , and wherein the vector in the compositions can be the same or different, whereupon an immune response against HSV is induced in the mammal.
18. A method of treating or preventing a Herpes Simplex Virus (HSV) disease in a mammal, which method comprises administering to the mammal a first administration of a composition and at least one additional administration of the same or different composition, wherein each of the administrations comprises the vector of claim 2 , and wherein the vector in the administrations of compositions can be the same or different, whereupon a HSV disease is treated or prevented in the mammal.
19. A method of inducing a T cell response against Herpes Simplex Virus (HSV) in a mammal, which method comprises administering to the mammal a first administration of a composition and at least one additional administration of the same or different composition, wherein each of the administrations comprises the vector of claim 2 , and wherein the vector in the administrations of compositions can be the same or different, whereupon a T cell response against HSV is induced in the mammal.
20. A method of inducing an antibody response against Herpes Simplex Virus (HSV) in a mammal, which method comprises administering to the mammal a first administration of a composition and at least one additional administration of the same or different composition, wherein each of the administrations comprises the vector of claim 2 , and wherein the vector in the administrations of compositions can be the same or different, whereupon an antibody response against HSV is induced in the mammal.
21. A method of treating or preventing a Herpes Simplex Virus (HSV) disease in a mammal, which method comprises administering to the mammal
(a) a first composition comprising the vector of claim 8 , and
(b) a second composition comprising the vector of 8 ,
wherein (i) the second composition is administered after the first composition, and (ii) the vector in the compositions are the same or different, whereupon the T cell response induced after administration of the first and second compositions is greater than the T cell response induced after administration of the first composition alone or the second composition alone, and a HSV disease is treated or prevented in the mammal.